FOLR1 and neoplasm: We previously demonstrated that treatment with MOv18 I.E. a monoclonal human/chimeric antibody engineered with Fc regions of the IgE class and specific for a tumour-associated antigen (TAA) (Folate Receptor alpha, FRα), triggered an immune-activatory TNFα/MCP-1 axis in tumours, which resulted in recruitment of macrophages into tumour lesions and was associated with significantly-reduced tumour growth [9], in a syngeneic immunocompetent lung metastases rat model.